ZMYND11 and prostate cancer: Collectively, these findings underscore the critical role of ZMYND11 downregulation in promoting prostate cancer cell growth and metastasis both in vitro and in vivo, consistent with the observed association between low ZMYND11 levels, aggressive prostate tumor phenotype, prostate cancer progression, and poor prognosis in clinical settings.